Medication Management for Diabetic Patient with CKD Stage 3b
Continue empagliflozin (Jardiance) at current dose, discontinue metformin immediately, and add a GLP-1 receptor agonist to achieve glycemic control. 1
Immediate Action: Discontinue Metformin
- Metformin is contraindicated at eGFR 32 mL/min/1.73 m² since this falls below the threshold of 30 mL/min/1.73 m² where metformin must be stopped. 1
- The FDA guidance explicitly states metformin is contraindicated when eGFR <30 mL/min/1.73 m², and while your patient is at 32, this is dangerously close to the contraindication threshold and requires immediate cessation. 1
- Even at eGFR 30-44 mL/min/1.73 m², metformin dose should be halved to maximum 1000 mg daily, but given the proximity to 30 and the availability of superior alternatives, discontinuation is the safest approach. 1, 2
Continue and Optimize SGLT2 Inhibitor Therapy
- Empagliflozin (Jardiance) should be continued at the current dose as SGLT2 inhibitors are recommended for patients with eGFR ≥20 mL/min/1.73 m² and provide kidney protection independent of glucose lowering. 1
- SGLT2 inhibitors slow CKD progression and reduce heart failure risk through mechanisms beyond glycemic control, including reduction of intraglomerular pressure, albuminuria, and oxidative stress. 1
- The EMPA-KIDNEY trial demonstrated that empagliflozin reduced progression of kidney disease or cardiovascular death by 28% (HR 0.72) in patients with eGFR as low as 20 mL/min/1.73 m². 3
- Continue empagliflozin until dialysis or transplantation is initiated. 1
Add GLP-1 Receptor Agonist for Glycemic Control
- A long-acting GLP-1 RA (semaglutide or dulaglutide preferred) should be added since the HbA1c of 8.1% indicates inadequate glycemic control despite current therapy. 1
- GLP-1 RAs are the preferred additional glucose-lowering agent after SGLT2 inhibitors and metformin, particularly when metformin cannot be used. 1
- These agents reduce cardiovascular events, slow CKD progression, and have minimal hypoglycemia risk. 1
- Semaglutide and dulaglutide have documented cardiovascular benefits and require no dose adjustment at this level of kidney function. 1
- Start with low doses and titrate slowly to minimize gastrointestinal side effects (e.g., dulaglutide 0.75 mg weekly initially, or semaglutide 0.25 mg weekly). 1
Consider Additional Kidney-Protective Therapy
- Evaluate for finerenone (nonsteroidal mineralocorticoid receptor antagonist) if albuminuria is present (albumin-to-creatinine ratio ≥30 mg/g) and potassium is normal. 1
- Finerenone provides additional cardiovascular and kidney protection when added to SGLT2 inhibitors in patients with type 2 diabetes and CKD. 4
- The CONFIDENCE trial showed that combination therapy with finerenone plus empagliflozin reduced albuminuria by 29-32% more than either agent alone. 4
- Monitor potassium closely if finerenone is initiated, though empagliflozin may partially mitigate hyperkalemia risk. 5
Monitoring Requirements
- Check eGFR and potassium every 3-6 months given the advanced CKD stage. 1
- Monitor for vitamin B12 deficiency if the patient was on metformin for >4 years prior to discontinuation. 1
- Assess blood pressure regularly as SGLT2 inhibitors and GLP-1 RAs both reduce systolic blood pressure. 1, 6
- Ensure the patient is on maximal tolerated RAS inhibitor therapy (ACE inhibitor or ARB) if not contraindicated. 1
Common Pitfalls to Avoid
- Do not continue metformin at eGFR <30 mL/min/1.73 m² despite perceived glycemic benefits—the lactic acidosis risk outweighs any advantage. 1
- Do not discontinue empagliflozin due to the low eGFR—SGLT2 inhibitors are safe and beneficial down to eGFR 20 mL/min/1.73 m². 1, 3
- Do not delay adding a GLP-1 RA while waiting for metformin washout—these agents can be started immediately. 1
- Do not use sulfonylureas as the next agent—they increase hypoglycemia risk and lack cardiovascular or kidney benefits. 1